Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial

Next Previous
Trial Profile

Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linrodostat (Primary) ; Nivolumab (Primary) ; Temozolomide
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions

Most Recent Events

  • 29 Jun 2025 Planned primary completion date changed from 15 Feb 2025 to 15 Feb 2027.
  • 15 Aug 2024 Planned End Date changed from 1 Jun 2025 to 1 Jun 2027.
  • 15 Aug 2024 Planned primary completion date changed from 22 Feb 2024 to 15 Feb 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top